JP2005523338A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005523338A5 JP2005523338A5 JP2003587532A JP2003587532A JP2005523338A5 JP 2005523338 A5 JP2005523338 A5 JP 2005523338A5 JP 2003587532 A JP2003587532 A JP 2003587532A JP 2003587532 A JP2003587532 A JP 2003587532A JP 2005523338 A5 JP2005523338 A5 JP 2005523338A5
- Authority
- JP
- Japan
- Prior art keywords
- arthritis
- disease
- inflammatory
- pharmaceutical composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010003246 arthritis Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010018634 Gouty Arthritis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010048873 Traumatic arthritis Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000005404 rubella Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37493802P | 2002-04-23 | 2002-04-23 | |
| PCT/US2003/012426 WO2003090912A1 (en) | 2002-04-23 | 2003-04-15 | Pyrrolo-triazine aniline compounds useful as kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010007097A Division JP5226018B2 (ja) | 2002-04-23 | 2010-01-15 | キナーゼ阻害剤として有用なピロロトリアジンアニリン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005523338A JP2005523338A (ja) | 2005-08-04 |
| JP2005523338A5 true JP2005523338A5 (https=) | 2006-04-27 |
| JP4669225B2 JP4669225B2 (ja) | 2011-04-13 |
Family
ID=29270573
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003587532A Expired - Fee Related JP4669225B2 (ja) | 2002-04-23 | 2003-04-15 | キナーゼ阻害剤として有用なピロロトリアジンアニリン化合物 |
| JP2010007097A Expired - Fee Related JP5226018B2 (ja) | 2002-04-23 | 2010-01-15 | キナーゼ阻害剤として有用なピロロトリアジンアニリン化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010007097A Expired - Fee Related JP5226018B2 (ja) | 2002-04-23 | 2010-01-15 | キナーゼ阻害剤として有用なピロロトリアジンアニリン化合物 |
Country Status (30)
| Country | Link |
|---|---|
| US (5) | US7160883B2 (https=) |
| EP (2) | EP2289894A3 (https=) |
| JP (2) | JP4669225B2 (https=) |
| KR (1) | KR101025675B1 (https=) |
| CN (2) | CN1662509A (https=) |
| AR (1) | AR039649A1 (https=) |
| AU (1) | AU2003231034B2 (https=) |
| BR (1) | BR0309669A (https=) |
| CA (1) | CA2483164C (https=) |
| DK (1) | DK1497019T3 (https=) |
| ES (1) | ES2543711T3 (https=) |
| GE (1) | GEP20074148B (https=) |
| HR (1) | HRP20040988A2 (https=) |
| HU (1) | HUE025353T2 (https=) |
| IL (2) | IL164573A (https=) |
| IS (1) | IS7505A (https=) |
| MX (1) | MXPA04010379A (https=) |
| MY (1) | MY132094A (https=) |
| NO (1) | NO329503B1 (https=) |
| NZ (1) | NZ536014A (https=) |
| PE (1) | PE20040590A1 (https=) |
| PL (1) | PL219736B1 (https=) |
| PT (1) | PT1497019E (https=) |
| RS (1) | RS92004A (https=) |
| RU (1) | RU2375363C2 (https=) |
| SI (1) | SI1497019T1 (https=) |
| TW (1) | TWI312782B (https=) |
| UA (1) | UA78562C2 (https=) |
| WO (1) | WO2003090912A1 (https=) |
| ZA (1) | ZA200408541B (https=) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6867300B2 (en) | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| US6670357B2 (en) * | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| PT1497019E (pt) * | 2002-04-23 | 2015-09-10 | Bristol Myers Squibb Co | Compostos de pirrolotriazina anilina úteis como inibidores de quinase |
| TW200400034A (en) | 2002-05-20 | 2004-01-01 | Bristol Myers Squibb Co | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
| TW200401638A (en) * | 2002-06-20 | 2004-02-01 | Bristol Myers Squibb Co | Heterocyclic inhibitors of kinases |
| TWI329112B (en) * | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| AU2003265349A1 (en) * | 2002-08-02 | 2004-02-23 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| TW200420565A (en) * | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
| JP2006516653A (ja) | 2003-02-05 | 2006-07-06 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤ピロロトリアジンの製造方法 |
| EP1667983A4 (en) * | 2003-09-23 | 2010-07-21 | Merck Sharp & Dohme | PYRAZOL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS |
| US7419978B2 (en) * | 2003-10-22 | 2008-09-02 | Bristol-Myers Squibb Company | Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors |
| US7309708B2 (en) * | 2003-11-20 | 2007-12-18 | Birstol-Myers Squibb Company | Hepatitis C virus inhibitors |
| AU2004299174A1 (en) * | 2003-12-10 | 2005-06-30 | Merck Patent Gmbh | Diacylhydrazine derivatives |
| US7102001B2 (en) | 2003-12-12 | 2006-09-05 | Bristol-Myers Squibb Company | Process for preparing pyrrolotriazine |
| AU2004309420B2 (en) * | 2003-12-23 | 2008-10-30 | Novartis Ag | Bicyclic heterocyclic p-38 kinase inhibitors |
| MY145634A (en) | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
| US7064203B2 (en) | 2003-12-29 | 2006-06-20 | Bristol Myers Squibb Company | Di-substituted pyrrolotriazine compounds |
| US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
| TW200538453A (en) * | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
| US7102002B2 (en) | 2004-06-16 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7173031B2 (en) * | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| US7432373B2 (en) * | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
| US7253167B2 (en) | 2004-06-30 | 2007-08-07 | Bristol-Myers Squibb Company | Tricyclic-heteroaryl compounds useful as kinase inhibitors |
| TW200600513A (en) | 2004-06-30 | 2006-01-01 | Bristol Myers Squibb Co | A method for preparing pyrrolotriazine compounds |
| US7102003B2 (en) | 2004-07-01 | 2006-09-05 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
| US7504521B2 (en) | 2004-08-05 | 2009-03-17 | Bristol-Myers Squibb Co. | Methods for the preparation of pyrrolotriazine compounds |
| TW200618803A (en) * | 2004-08-12 | 2006-06-16 | Bristol Myers Squibb Co | Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors |
| US7151176B2 (en) * | 2004-10-21 | 2006-12-19 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds |
| ES2350771T3 (es) * | 2004-10-26 | 2011-01-26 | Novartis Ag | Pirrolo [1,2-d][1,2-4]triazina como inhibidores de quinasas c-jun n-terminal (jnk) y quinasas p-38. |
| US7534882B2 (en) | 2005-04-06 | 2009-05-19 | Bristol-Myers Squibb Company | Method for preparing pyrrolotriazine compounds via in situ amination of pyrroles |
| US20060235020A1 (en) * | 2005-04-18 | 2006-10-19 | Soojin Kim | Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein |
| US7405213B2 (en) * | 2005-07-01 | 2008-07-29 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
| US7442700B2 (en) * | 2005-07-01 | 2008-10-28 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
| US7402582B2 (en) * | 2005-07-01 | 2008-07-22 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
| US7348325B2 (en) * | 2005-11-30 | 2008-03-25 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US8063208B2 (en) | 2006-02-16 | 2011-11-22 | Bristol-Myers Squibb Company | Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol |
| KR20080107408A (ko) | 2006-03-07 | 2008-12-10 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 억제제로서 유용한 피롤로트리아진 아닐린 전구약물화합물 |
| US7531539B2 (en) | 2006-08-09 | 2009-05-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US8268998B2 (en) | 2006-11-03 | 2012-09-18 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7982033B2 (en) | 2006-11-03 | 2011-07-19 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| ES2539620T3 (es) | 2008-12-19 | 2015-07-02 | Cephalon, Inc. | Pirrolotriazina como inhibidor de ALK y de JAK2 |
| US8399451B2 (en) * | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
| ES2548683T3 (es) | 2010-04-23 | 2015-10-20 | Bristol-Myers Squibb Company | Amidas del ácido 4-(5-isoxazolil o 5-pirrazolil-1,2,4-oxadiazol-3-il)-mandélico como agonistas de receptor de esfingosina-1-fosfato 1 |
| WO2012031057A1 (en) | 2010-09-01 | 2012-03-08 | Bristol-Myers Squibb Company | Bms- 582949 for the treatment of resistant rheumatic disease |
| EP2619190B1 (en) | 2010-09-24 | 2015-08-12 | Bristol-Myers Squibb Company | Substituted oxadiazole compounds and their use as s1p1 agonists |
| WO2014082230A1 (zh) * | 2012-11-28 | 2014-06-05 | 上海希迈医药科技有限公司 | 吡咯并三嗪类衍生物、其制备方法及其在医药上的应用 |
| CN103848833B (zh) * | 2012-11-28 | 2016-08-31 | 上海希迈医药科技有限公司 | 吡咯并三嗪类衍生物、其制备方法及其在医药上的应用 |
| US9447105B2 (en) | 2013-01-24 | 2016-09-20 | Council Of Scientific & Industrial Research | Triazine compounds and a process for preparation thereof |
| CN103601722B (zh) * | 2013-09-13 | 2016-03-02 | 南京华威医药科技开发有限公司 | 新型抗肿瘤化合物 |
| EP3054955B1 (en) * | 2013-10-11 | 2018-05-30 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| SI3057969T1 (sl) | 2013-10-17 | 2018-10-30 | Blueprint Medicines Corporation | Sestavki, uporabni za zdravljenje motenj, povezanih s KIT |
| WO2015091156A1 (en) | 2013-12-17 | 2015-06-25 | Boehringer Ingelheim International Gmbh | Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions |
| WO2018129301A1 (en) * | 2017-01-05 | 2018-07-12 | Biodesix, Inc. | Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups |
| US11040979B2 (en) | 2017-03-31 | 2021-06-22 | Blueprint Medicines Corporation | Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR |
| BR112020006677A2 (pt) | 2017-10-05 | 2020-10-06 | Fulcrum Therapeutics, Inc. | uso de inibidores p38 para reduzir a expressão de dux4 |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| WO2019168874A1 (en) | 2018-02-27 | 2019-09-06 | The Research Foundation For The State University Of New York | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
| EP3762379A1 (en) | 2018-03-07 | 2021-01-13 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
| ES2966512T3 (es) | 2019-04-12 | 2024-04-22 | Blueprint Medicines Corp | Formas cristalinas de (S)-1-(4-fluorofenil)-1-(2-(4-(6-(1-metil-1H-pirazol-4-il)pirrolo[2,1-f][1,2,4]triazin-4-il)piperazinil)-pirimidin-5-il)etan-1-amina y métodos de elaboración |
| BR112021020441A2 (pt) | 2019-04-12 | 2021-12-14 | Blueprint Medicines Corp | Derivados de pirrolotriazina para tratar doenças mediadas por kit e pdgfra |
| TW202112368A (zh) | 2019-06-13 | 2021-04-01 | 荷蘭商法西歐知識產權股份有限公司 | 用於治療有關dux4表現之疾病的抑制劑組合 |
| CN110483439B (zh) * | 2019-08-28 | 2022-12-30 | 郑州手性药物研究院有限公司 | 6-氨基甲基-1,1-二氧-1,2-苯并噻唑-3-酮的合成方法 |
| CN110483497B (zh) * | 2019-08-28 | 2022-12-30 | 郑州手性药物研究院有限公司 | 6-氨基甲基-1,1-二氧-1,2-苯并噻唑-3-酮中间体及其合成方法 |
| CN110627706B (zh) * | 2019-08-28 | 2023-02-10 | 郑州手性药物研究院有限公司 | 2-(4-甲基苄基)-1h-异吲哚-1,3-二酮衍生物及其合成方法 |
| CN121159543A (zh) * | 2025-09-19 | 2025-12-19 | 合肥综合性国家科学中心大健康研究院 | 吡咯并[2,1-f][1,2,4]三嗪类化合物及其制备方法和应用、中间体、药物组合物和cGAS激动剂 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3629301A (en) | 1969-10-24 | 1971-12-21 | Du Pont | 3 3-difluoro-2-substituted steroids and their preparation |
| US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| IL107041A (en) * | 1992-09-25 | 2000-02-17 | Lilly Co Eli | Process for preparing omega(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo-6-¬2,3-d¾pyrimidin-5-YL)alkarylcarboxylic acids and N-(omega-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo¬2,3-d¾pyrimidin-5-YL)alk-aroyl-4-glutamic acids |
| IL118544A (en) | 1995-06-07 | 2001-08-08 | Smithkline Beecham Corp | History of imidazole, the process for their preparation and the pharmaceutical preparations containing them |
| PL187516B1 (pl) | 1996-01-11 | 2004-07-30 | Smithkline Beecham Corp | Nowe podstawione pochodne imidazolu, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca te związki |
| US6191131B1 (en) * | 1997-07-23 | 2001-02-20 | Dupont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| US5945418A (en) | 1996-12-18 | 1999-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| US6147080A (en) | 1996-12-18 | 2000-11-14 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
| IL132736A0 (en) | 1997-05-22 | 2001-03-19 | Searle & Co | 3(5)-Heteroaryl substituted pyrazoles as p38 kinase inhibitors |
| US6087496A (en) | 1998-05-22 | 2000-07-11 | G. D. Searle & Co. | Substituted pyrazoles suitable as p38 kinase inhibitors |
| US6251914B1 (en) | 1997-07-02 | 2001-06-26 | Smithkline Beecham Corporation | Cycloalkyl substituted imidazoles |
| WO1999024033A1 (en) * | 1997-11-12 | 1999-05-20 | Shionogi & Co., Ltd. | Method for the treatment of disorders associated with apoptosis using n-heterocyclic glyoxylamide compounds |
| US6130235A (en) | 1998-05-22 | 2000-10-10 | Scios Inc. | Compounds and methods to treat cardiac failure and other disorders |
| US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| MXPA01002173A (es) | 1998-08-28 | 2003-07-14 | Scios Inc | Inhibidores de p38-alfa cinasa. |
| JP2002526482A (ja) * | 1998-09-18 | 2002-08-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｐ３８のインヒビター |
| ATE232205T1 (de) | 1998-10-01 | 2003-02-15 | Astrazeneca Ab | Chinolin- und chinazolin derivate und ihre verwendung als inhibitoren von krankheiten, bei denen cytokine beteiligt wird |
| CA2346334A1 (en) * | 1998-10-14 | 2000-04-20 | Shionogi & Co., Ltd. | Composition for treating or preventing ischemia reperfusion injury |
| GB9906566D0 (en) | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
| US6982265B1 (en) | 1999-05-21 | 2006-01-03 | Bristol Myers Squibb Company | Pyrrolotriazine inhibitors of kinases |
| JP4649046B2 (ja) * | 1999-05-21 | 2011-03-09 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼのピロロトリアジン阻害剤 |
| US6787545B1 (en) * | 1999-08-23 | 2004-09-07 | Shiongi & Co., Ltd. | Pyrrolotriazine derivatives having spla2-inhibitory activities |
| GB9924092D0 (en) | 1999-10-13 | 1999-12-15 | Zeneca Ltd | Pyrimidine derivatives |
| ES2237470T3 (es) | 1999-11-10 | 2005-08-01 | Ortho-Mcneil Pharmaceutical, Inc. | 2-aril-3-(heteroaril)-imidazo(1,2-alfa)pirimidinas sustituidas; y composiciones farmaceuticas y procedimientos asociados. |
| US20020065270A1 (en) * | 1999-12-28 | 2002-05-30 | Moriarty Kevin Joseph | N-heterocyclic inhibitors of TNF-alpha expression |
| US6906067B2 (en) * | 1999-12-28 | 2005-06-14 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-α expression |
| US6867300B2 (en) * | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
| GEP20063915B (en) * | 2000-11-17 | 2006-09-11 | Bristol Myers Squibb Co | PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS AND USE THEREOF FOR TREATING p38 KINASE-ASSOCIATED CONDITIONS |
| US6670357B2 (en) * | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| AU2002316421B2 (en) * | 2001-06-26 | 2008-05-15 | Bristol-Myers Squibb Company | N-heterocyclic inhibitors of TNF-ALPHA expression |
| TW200300350A (en) * | 2001-11-14 | 2003-06-01 | Bristol Myers Squibb Co | C-5 modified indazolylpyrrolotriazines |
| TW200306841A (en) * | 2002-04-23 | 2003-12-01 | Bristol Myers Squibb Co | Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors |
| PT1497019E (pt) * | 2002-04-23 | 2015-09-10 | Bristol Myers Squibb Co | Compostos de pirrolotriazina anilina úteis como inibidores de quinase |
| TW200400034A (en) * | 2002-05-20 | 2004-01-01 | Bristol Myers Squibb Co | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
| TWI329112B (en) * | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| TWI272271B (en) * | 2002-07-19 | 2007-02-01 | Bristol Myers Squibb Co | Process for preparing certain pyrrolotriazine compounds |
| AU2003265349A1 (en) * | 2002-08-02 | 2004-02-23 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| TW200420565A (en) * | 2002-12-13 | 2004-10-16 | Bristol Myers Squibb Co | C-6 modified indazolylpyrrolotriazines |
| JP2006516653A (ja) * | 2003-02-05 | 2006-07-06 | ブリストル−マイヤーズ スクイブ カンパニー | キナーゼ阻害剤ピロロトリアジンの製造方法 |
| MY145634A (en) * | 2003-12-29 | 2012-03-15 | Bristol Myers Squibb Co | Pyrrolotriazine compounds as kinase inhibitors |
| TW200600513A (en) * | 2004-06-30 | 2006-01-01 | Bristol Myers Squibb Co | A method for preparing pyrrolotriazine compounds |
| US7504521B2 (en) * | 2004-08-05 | 2009-03-17 | Bristol-Myers Squibb Co. | Methods for the preparation of pyrrolotriazine compounds |
| US7534882B2 (en) * | 2005-04-06 | 2009-05-19 | Bristol-Myers Squibb Company | Method for preparing pyrrolotriazine compounds via in situ amination of pyrroles |
| US20060235020A1 (en) * | 2005-04-18 | 2006-10-19 | Soojin Kim | Process for preparing salts of 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide and novel stable forms produced therein |
| KR20080107408A (ko) * | 2006-03-07 | 2008-12-10 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 억제제로서 유용한 피롤로트리아진 아닐린 전구약물화합물 |
-
2003
- 2003-04-15 PT PT37241577T patent/PT1497019E/pt unknown
- 2003-04-15 HR HR20040988A patent/HRP20040988A2/hr not_active Application Discontinuation
- 2003-04-15 DK DK03724157.7T patent/DK1497019T3/en active
- 2003-04-15 MX MXPA04010379A patent/MXPA04010379A/es active IP Right Grant
- 2003-04-15 SI SI200332435T patent/SI1497019T1/sl unknown
- 2003-04-15 NZ NZ536014A patent/NZ536014A/en not_active IP Right Cessation
- 2003-04-15 CN CN038142937A patent/CN1662509A/zh active Pending
- 2003-04-15 EP EP10178247A patent/EP2289894A3/en not_active Withdrawn
- 2003-04-15 GE GEAP8506A patent/GEP20074148B/en unknown
- 2003-04-15 AU AU2003231034A patent/AU2003231034B2/en not_active Ceased
- 2003-04-15 BR BR0309669-6A patent/BR0309669A/pt not_active Application Discontinuation
- 2003-04-15 PL PL373338A patent/PL219736B1/pl unknown
- 2003-04-15 WO PCT/US2003/012426 patent/WO2003090912A1/en not_active Ceased
- 2003-04-15 UA UA20041109628A patent/UA78562C2/uk unknown
- 2003-04-15 ES ES03724157.7T patent/ES2543711T3/es not_active Expired - Lifetime
- 2003-04-15 CN CN201010616344.7A patent/CN102093363B/zh not_active Expired - Fee Related
- 2003-04-15 JP JP2003587532A patent/JP4669225B2/ja not_active Expired - Fee Related
- 2003-04-15 EP EP20030724157 patent/EP1497019B1/en not_active Expired - Lifetime
- 2003-04-15 RU RU2004134337/04A patent/RU2375363C2/ru not_active IP Right Cessation
- 2003-04-15 HU HUE03724157A patent/HUE025353T2/en unknown
- 2003-04-15 RS YU92004A patent/RS92004A/sr unknown
- 2003-04-15 KR KR1020047017020A patent/KR101025675B1/ko not_active Expired - Fee Related
- 2003-04-15 CA CA2483164A patent/CA2483164C/en not_active Expired - Fee Related
- 2003-04-18 TW TW092109121A patent/TWI312782B/zh not_active IP Right Cessation
- 2003-04-22 MY MYPI20031516A patent/MY132094A/en unknown
- 2003-04-22 US US10/420,399 patent/US7160883B2/en not_active Expired - Lifetime
- 2003-04-23 AR ARP030101401A patent/AR039649A1/es not_active Application Discontinuation
- 2003-04-23 PE PE2003000402A patent/PE20040590A1/es not_active Application Discontinuation
-
2004
- 2004-10-14 IL IL164573A patent/IL164573A/en not_active IP Right Cessation
- 2004-10-14 IS IS7505A patent/IS7505A/is unknown
- 2004-10-21 ZA ZA2004/08541A patent/ZA200408541B/en unknown
- 2004-10-22 NO NO20044560A patent/NO329503B1/no not_active IP Right Cessation
-
2006
- 2006-10-24 US US11/585,598 patent/US7462616B2/en not_active Expired - Lifetime
-
2007
- 2007-08-30 IL IL185604A patent/IL185604A0/en unknown
-
2008
- 2008-10-28 US US12/259,483 patent/US7759343B2/en not_active Expired - Lifetime
-
2010
- 2010-01-15 JP JP2010007097A patent/JP5226018B2/ja not_active Expired - Fee Related
- 2010-06-03 US US12/793,016 patent/US20100240646A1/en not_active Abandoned
- 2010-12-31 US US12/983,048 patent/US20110098467A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005523338A5 (https=) | ||
| JP2005529890A5 (https=) | ||
| JP2005531584A5 (https=) | ||
| JP2005511722A5 (https=) | ||
| EP2277505A3 (en) | Mucoactive agents for treating a pulmonary disease | |
| JP2023106403A5 (https=) | ||
| NO20025221D0 (no) | Nytt preparat | |
| JP2006510676A5 (https=) | ||
| JP2007514637A5 (https=) | ||
| JP2008508303A5 (https=) | ||
| SE0200356D0 (sv) | Novel use | |
| JP2012255002A5 (https=) | ||
| JP2005533005A5 (https=) | ||
| CY1109194T1 (el) | Παραγωγα ν-υδροξυαμιδιου και η χρηση του | |
| IL167900A (en) | Use of betamimetics to prepare a medical preparation for the treatment of chronic obstructive pulmonary disease | |
| JP2004534769A5 (https=) | ||
| EA200200551A1 (ru) | Новые содержащие тиотропий порошки для ингаляции | |
| UA83813C2 (ru) | Порошковое лекарственное средство, которое содержит соль тиотропия и ксинафоат салметерола | |
| JP2016517446A5 (https=) | ||
| RU2005106356A (ru) | Новое соединение | |
| RU2005106355A (ru) | Новое соединение | |
| NZ547523A (en) | Novel tiotropium salts, methods for the production thereof, and pharmaceutical formulations containing the same | |
| JP2007520507A5 (https=) | ||
| CY1108420T1 (el) | Προτοτυπο τιοτροπιουχο κονιωδες σκευασμα για εισπνοη | |
| Sivasankarapillai et al. | Role of nanotechnology in facing SARS-CoV-2 pandemic: solving crux of the matter with a hopeful arrow in the quiver |